-
1
Repressed chromatin drives leukaemogenesis in mutant IDH2 acute myeloid leukaemia via inhibition of granulocyte differentiation and cell cycle progression
Published 2021“…American Society of Hematology…”
Conference item -
2
Single Cell Analysis of Acquired Pomalidomide-Resistance in Multiple Myeloma Cell Lines Reveals Distinct Subclonal Cereblon Mutations and Gene Expression Heterogeneity
Published 2018“…American Society of Hematology…”
Conference item -
3
Loss Of COP9-signalosome genes Aa 2q37 is associated with IMiD agent resistance in multiple myeloma
Published 2022“…American Society of Hematology…”
Journal article -
4
Clonal heterogeneity in differentiation response and resistance to the IDH2 inhibitor enasidenib in acute myeloid leukemia
Published 2017“…American Society of Hematology…”
Conference item -
5
Loss of COP9 signalosome gene-containing 2q region is associated with lenalidomide and pomalidomide resistance in myeloma patients
Published 2021“…American Society of Hematology…”
Conference item -
6
Multiple cereblon genetic changes are associated with acquired resistance to lenalidomide or pomalidomide in multiple myeloma
Published 2020“…American Society of Hematology…”
Journal article -
7
Enasidenib induces acute myeloid leukemia cell differentiation to promote clinical response
Published 2017“…American Society of Hematology…”
Journal article